Lipoprotein(a) and Insulin Resistance Drive CVD Risk in MASLD
Personalized briefing
Discovery of the day · Diabetes
Lipoprotein(a), insulin resistance, and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease
Dear Dr. Vijay Viswanathan, this is your personalized scientific intelligence briefing — curated for your work in Diabetes.
Key finding
Medicine · Diabetes
Discovery of the day
This study demonstrates that elevated lipoprotein(a) and insulin resistance jointly amplify cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers found that the combination of high Lp(a) levels and insulin resistance was independently associated with a significantly increased incidence of major adverse cardiovascular events. For a diabetes specialist managing patients with NAFLD/MASLD—a population at high risk for both hepatic and cardiovascular complications—this evidence supports incorporating Lp(a) screening into routine cardiovascular risk stratification to identify those who may benefit from more aggressive metabolic and lipid-lowering interventions.
Novelty
78%
Rigor
85%
Significance
82%
Validity
84%
Clarity
90%
Advertisement
ScientificChina — The Global Marketplace for Scientific and Medical Equipments Start Browsing →
Your briefing is personalized based on your selected fields, keywords, and research interests.
